Related Experiment Videos

Increasing use of SGLT-2 inhibitors among patients with heart failure

Natalie Hoppe1, Susan Haugh, Audrey Umbreit

  • 1At Mayo Clinic Health System, Natalie Hoppe is an advanced practice registered nurse in the Department of Cardiology in Mankato, MN; Susan Haugh is a nurse practitioner in cardiology and supervisor of cardiology advanced practice providers at multiple locations throughout Minnesota; Audrey Umbreit is a senior pharmacy manager of clinical practice in primary care in the Department of Pharmacy in Mankato, MN; Marisa Morlock is a PA in the Department of Cardiology in Mankato, MN; Jill Sathre is a clinical pharmacist in the Department of Pharmacy in Austin, MN; Jennifer Johnson is a physician in the Department of Family Medicine in Mankato, MN, and medical director of the Medical Weight Management Clinic in Mankato, MN; Katie Machacek is a nurse practitioner in the Department of Cardiology in Austin, MN; Katie Hinderaker is chief of staff at the Mayo Clinic Lake City Medical Center in Lake City, MN, and a consultant in the Department of Family Medicine in Lake City, MN; Ahmad Al-Anii is a physician in the Department of Internal Medicine in Austin, MN; and Alexandra Bates is a performance improvement advisor in Quality Management Services in Mankato, MN. The authors have disclosed no potential conflicts of interest, financial or otherwise.

JAAPA : Official Journal of the American Academy of Physician Assistants
|October 27, 2026
PubMed
Abstract

Keywords:
SGLT-2 inhibitorscardiologyguideline-directed medical therapyheart failuremultidisciplinaryquality improvement

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...